Primary Lymphoma of the Thyroid: Diagnostic and Therapeutic Considerations  by Sarinah, Basro & Hisham, Abdullah-Noor
20 ASIAN JOURNAL OF SURGERY VOL 33 • NO 1 • JANUARY 2010
© 2010 Elsevier. All rights reserved.
Original Article
Primary Lymphoma of the Thyroid: Diagnostic and
Therapeutic Considerations
Basro Sarinah and Abdullah Noor Hisham, Department of Breast and Endocrine Surgery, Hospital Putrajaya,
Putrajaya, Malaysia.
BACKGROUND: Primary thyroid lymphoma is uncommon and accounts for less than 2–5% of all 
thyroid malignancies. The aim of the present study was to review our experience and management of 
primary thyroid lymphoma and to discuss the diagnostic and therapeutic considerations.
METHODS: Eleven women and six men with primary thyroid lymphoma were diagnosed and managed
in our department between October 1998 and March 2006. The clinical course and pathological spec-
trum of this disorder affecting the thyroid gland were reviewed.
RESULTS: Twelve patients had a prior history of thyroid disease. Clinical symptoms included a rapidly
enlarging neck mass (88%), dyspnoea (65%), dysphagia (53%) and hoarseness of voice (35%). Five patients
were hypothyroid at the time of diagnosis. Fifteen patients underwent fine-needle aspiration cytology
(FNAC). Six patients had an initial diagnosis of lymphocytic thyroiditis. FNAC results were highly sug-
gestive of thyroid lymphoma in only five patients. In the remaining patients, FNAC results showed a fol-
licular lesion in two patients and were inconclusive in the other two patients. A further incisional biopsy
was performed in five patients, and a diagnosis of non-Hodgkin’s lymphoma (NHL) was confirmed in
four patients and inconclusive in one. Five patients had a core biopsy. Four revealed NHL and one had
lymphocytic thyroiditis. Nine patients underwent surgery; three of whom had emergency debulking of
the tumour for acute airway obstruction. A final diagnosis of thyroid lymphoma was confirmed in all
these patients. Sixteen patients had B-cell and one had T-cell NHL. Fifteen patients received combination
chemotherapy with or without irradiation. All tumours dramatically decreased in size soon after initia-
tion of treatment. Overall survival was 82%, with a mean follow-up of 19 months.
CONCLUSION: The diagnosis of primary thyroid lymphoma should be considered when dealing with
rapidly growing goitres. The role of FNAC in diagnosing thyroid lymphoma is limited but it is still useful
in the initial work-up. Nevertheless, surgical intervention is often required to establish the diagnosis and
relieve critical airway compression. A combination of chemotherapy and irradiation is the mainstay of
management. [Asian J Surg 2010;33(1):20–24]
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Introduction
Primary thyroid lymphoma is an uncommon malignancy.
In most series, it comprises 0.6–5% of all thyroid cancers
and <2% of extranodal lymphomas.1,2 Frequently, based on
histology and fine-needle aspiration cytology (FNAC), it is
difficult to distinguish between anaplastic carcinoma and
thyroid lymphoma. In most instances, thyroid lymphoma
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is diagnosed only after thyroid surgery for suspicious car-
cinoma has been performed.3 The increased use of im-
munocytochemical lymphoid markers has improved the
diagnosis and categorization of thyroid lymphoma.4 It is
now believed that cases previously diagnosed as anaplas-
tic carcinoma could well be primary thyroid lymphoma.
Recent onset of symptoms or a rapid change in size of a
pre-existing thyroid mass are the hallmarks of both thyroid
lymphoma and anaplastic carcinoma.5,6 It is important to
distinguish between these two tumours because anaplastic
carcinoma has a much poorer prognosis, with few patients
surviving beyond 2 years, whereas primary thyroid lym-
phoma has a favourable outcome with cyclophosphamide-
based multimodality chemotherapy in combination with
radiotherapy.7–9
Patients and methods
All patients diagnosed with primary thyroid lymphoma in
our department from September 1998 to March 2006
were enrolled in this prospective study. The clinical course
and pathological spectrum of this disorder as it affected
the thyroid gland were reviewed.
A total of 17 patients, 11 women and 6 men, were man-
aged over a period of 92 months. The mean age at presen-
tation was 58 years, with a range of 31 to 82 years. Fifteen
patients (88%) presented with a rapidly enlarging anterior
neck mass; 12 of them had a history of pre-existing goitre
(70%) with a mean duration of 7 years. Other associated
symptoms included dyspnoea (65%), dysphagia (53%),
hoarseness of voice (35%), and pain over the thyroid swell-
ing (12%). Six patients also experienced associated consti-
tutional symptoms such as loss of weight or appetite, and
one patient had fever.
Results
All 17 patients had palpable goitre. Four patients had clin-
ically palpable cervical lymph nodes. However, imaging
studies showed the presence of cervical lymph nodes in 11
cases. Eleven of our patients were euthyroid (65%), five were
hypothyroid (29%), and one presented with mild hyperthy-
roidism upon treatment (6%). Anti-microsomal and anti-
thyroglobulin antibodies were only done in seven patients,
and were found to be elevated in five of these patients.
Fifteen patients had FNAC performed, which revealed
lymphocytic thyroiditis in six patients, and a high suspicion
of thyroid lymphoma in five patients. In the remaining
patients, FNAC results showed a follicular lesion in two
patients, and were inconclusive in the other two patients.
In one patient with an initial FNAC diagnosis of lympho-
cytic thyroiditis, repeat examination after 1 year was sug-
gestive of either non-Hodgkin’s lymphoma (NHL) or
high-grade anaplastic carcinoma (Table 1).
Five of our patients had a core biopsy performed. Four
were confirmed with NHL and one was confirmed with
lymphocytic thyroiditis. Five patients had an open biopsy
performed, and four were confirmed with. Nine patients
underwent thyroidectomy; four of them were operated on
in an emergency setting; tumour debulking was done for
acute airway obstruction in three patients, and for severe
pain in the other (Table 2).
In three patients who underwent thyroidectomy, the
diagnosis of NHL was unsuspected preoperatively, and
their initial FNAC result indicated lymphocytic thyroidi-
tis. One patient underwent thyroidectomy for clinical sus-
picion of follicular malignancy. However, in one patient
who was highly suspicious for lymphoma, all diagnostic
investigations with FNAC, two repeated core biopsies, and
a final open biopsy were inconclusive. It was only after
thyroidectomy for significant pressure symptoms that a
diagnosis of NHL was confirmed (Table 3).
Histologically, 16 of our patients had B-cell NHL and
one had T-cell NHL. The latter was a 54-year-old Chinese
woman who had a history of pre-existing goitre for 
20 years, with sudden enlargement for 2 months. Sub-
sequent staging and work-up of all these patients included
computed tomography of the mediastinum and abdo-
men, and bone marrow aspiration. Six of our patients pre-
sented in stage IE (35%) and 11 patients in stage IIE (65%).
In 15 patients, treatment constituted of chemother-
apy (CHOP regimen: cyclophosphamide, doxorubicin,
vincristine and prednisolone) with or without radiother-
apy. In all cases, a dramatic decrease in tumour size was
noted after initiation of treatment. All patients except one
are still alive without any relapse. Our overall survival was
82%, with a mean follow-up of 19 months (range: 2–30
months). One patient who underwent emergency tumour
debulking for acute respiratory distress defaulted after
two cycles of chemotherapy. Following this, the tumour
reappeared and he succumbed 6 months after surgery,
despite restarting chemotherapy.
The other two patients who underwent emergency
debulking surgery for acute airway obstruction also died.
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One was an 81-year-old woman who was too fragile for
postoperative chemotherapy, and recurrence was detected
after 1 month. She was given radiotherapy but responded
poorly and succumbed to the disease 4 months after sur-
gery. The other patient died from aspiration pneumonia
5 days postoperatively.
Discussion
NHL of the thyroid tends to have a female predominance.
In our series, it was a 1.8:1 female to male ratio but others
have reported it to be as high as 4:1.10,11 Clinically, it can
mimic anaplastic thyroid carcinoma in that both have
similar clinical characteristics of rapid growth, which
might be associated with dyspnoea, dysphagia, pain and
hoarseness of voice. NHL of the thyroid usually presents
in the 5th to 7th decades of life. A large number of these
cases had a prior history of Hashimoto’s thyroiditis (range:
40–80%).2,12
It is accepted widely that patients with Hashimoto’s
thyroiditis have a greater risk of subsequently developing
thyroid lymphoma, with an overall 60–80-fold higher risk
than in the general population.13 It is estimated that 1 in
200 cases of Hashimoto’s disease goes on to develop pri-
mary thyroid lymphoma. There is also evidence that large-
cell lymphoma probably evolves from persistent low-grade
mucosa-associated lymphoid tissue (MALT) malignant
lymphoma, suggesting a morphological progression from
chronic lymphocytic thyroiditis to low-grade MALT lym-
phoma, and subsequently, to high-grade large-cell lym-
phoma.1 The time interval between the diagnosis of
Hashimoto’s thyroiditis and the subsequent development
of malignant lymphoma of the thyroid is approximately
9–10 years.14
FNAC has an established role in the management 
of thyroid nodules and goitres. However, its role in diag-
nosing thyroid lymphoma is limited because the small
yield from FNAC makes the cytological differentiation of
thyroid lymphoma from lymphocytic thyroiditis and
anaplastic carcinoma difficult.15 Furthermore, the yield
from FNAC may not be representative. Therefore, al-
though FNAC is usually used in the initial work-up of all
thyroid patients, a core needle or open biopsy is often 
required to diagnose thyroid NHL. Occasionally, even
thyroidectomy is required.
FNAC frequently reveals lymphocytes that are often
interpreted as evidence for the presence of thyroiditis. The
histological differentiation between pre-existing thyroidi-
tis and thyroid lymphoma is often difficult and can lead
to an underestimate in the reporting of the association.2,16
Scholefield et al16 have concluded that serial autoanti-
body assays in patients with Hashimoto’s thyroiditis might
be necessary to help predict the onset of lymphomatous
change in this condition.
Cases of high-grade lymphoma can be confused with
anaplastic carcinoma, but this distinction can be made
easily on immunohistochemical grounds using antibodies
to cytokeratins and leukocyte common antigens. The es-
sential difference between a reactive and a neoplastic lym-
phoid infiltrate is the presence of light chain restriction
in the latter.17 Lymphoma tumours usually have a diffuse
growth pattern; residual follicles are often seen within the
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Table 1. Fine needle aspiration cytology (FNAC)
FNAC results No. of patients (%)
Lymphocytic thyroiditis 6 (40)
Suggestive of lymphoid malignancy 5 (34)
Follicular lesion/neoplasm 2 (13)
Inconclusive 2 (13)
Total 15 (100)
Table 2. Diagnostic procedures
Diagnostic procedures No. of patients (%)
Trucut biopsy 4 (23.5)




Debulking of tumour 4
Table 3. Indication for surgery
Indication for surgery No. of patients (%)
Unsuspected of NHL 3
(FNAC: lymphocytic thyroiditis)
Clinical suspicion of follicular 1
malignancy
Acute airway obstruction 3
Severe pain 1
Core and open biopsy were inconclusive 1
Total 9
NHL = non-Hodgkin’s lymphoma; FNAC = fine-needle aspiration
cytology.
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tumour at the border. It is of particular interest that tu-
mour cells might also be present in these follicles (Figure 1).
Similar to the findings of the present study, most thy-
roid lymphomas are of B-cell origin and predominantly
of diffuse large-cell type.1,2,11,18 The second most common
histological type is MALT lymphoma.11,18 Other less fre-
quently encountered types include Hodgkin’s disease,
Burkitt’s lymphoma and plasmacytoma. T-cell lymphoma
is extremely rare, with only a few cases reported in the lit-
erature. Most of the T-cell lymphomas reported have been
in Asia. In general, T-cell lymphoma is associated with a
worse prognosis than is B-cell lymphoma.19,20
The choice of treatment in primary thyroid lymphoma
is based on the histological subtype of the neoplasm, its
stage, and the tumour bulk, as well as the other associated
comorbid factors. Similar to previous studies,11,21–23 the
majority of patients with thyroid lymphoma in the cur-
rent study presented with stage I and II disease (about
80%). The staging is adopted from the Ann Arbor system
for Hodgkin’s disease. The overall survival ranges from
35% to 79%.11,23–26 The 5-year survival for each stage is
80% for stage IE, 50% stage for IIE and < 36% for stage 
IIIE and IVE.26
Several prospective randomized trials have shown an
advantage in combining chemotherapy with radiotherapy
for patients with stage I and II intermediate- and high-
grade NHL.23,27 A review of 211 patients with NHL local-
ized to the thyroid gland has revealed that overall and
distant recurrence rates were significantly reduced in
patients who were treated with a combination of systemic
chemotherapy and radiation, in contrast to those who
were treated with radiotherapy alone (overall recurrence:
7.7% vs. 37%; distant recurrence: 5.1% vs. 30.8%).8 A similar
relapse rate of 30% has been reported by DiBiase et al.23
Most centres advocate the CHOP chemotherapy regimen.
Pedersen and Pedersen24 have reported that histologi-
cal grade is not a statistically significant factor in survival;
however, it is significant in stage IIIE and IVE disease. In
contrast, Laing et al25 have reported that the presence of
histopathological features of MALT is a statistically sig-
nificant factor in patient survival and also a favourable
prognostic factor for high-grade lymphoma. Lymphoma
of non-MALT origin has a poorer prognosis. The overall
cause-specific survival at 5 years for patients with NHL of
MALT origin was 90% compared with 55% for those with-
out evidence of MALT origin.
A B
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Figure 1. Diffuse large-cell type malignant lymphoma. (A)
Malignant lymphoid cells diffusely infiltrated the thyroid gland
with residual thyroid follicles [haematoxylin and eosin (H&E)
stain, low magnification]. (B) Neoplastic cells with rounded
nuclei and central nucleoli surrounding the thyroid follicle
(H&E stain, high magnification). (C) Neoplastic cells plugging
into the thyroid follicle (H&E stain, higher magnification).
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The role of the surgeon in the treatment and diagnosis
of thyroid lymphoma has evolved from surgical debulk-
ing to open biopsy. With the use of irradiation and che-
motherapy, the need for surgery has nearly disappeared,
except in those patients who present with significant air-
way compromise. A study by Rebecca et al28 on 27 patients
with thyroid lymphoma and significant airway obstruc-
tion who underwent palliative surgery showed good long-
term palliation (overall 5-year survival of 77%) and low
operative morbidity.
The diagnosis of primary thyroid lymphoma should
be considered when dealing with rapidly growing goitres.
FNAC is a useful first step in diagnosing thyroid cancers;
surgical intervention is confined mainly to critical airway
compression with resection of the thyroid mass and to
some extend incisional biopsy for a confirmatory diagno-
sis. A combined modality of treatment with chemother-
apy and irradiation is the mainstay of management of
thyroid lymphoma.
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